Profile data is unavailable for this security.
About the company
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
- Revenue in USD (TTM)210.00k
- Net income in USD-10.74m
- Incorporated1982
- Employees4.00
- LocationAnixa Biosciences Inc3150 Almaden Expy Ste 250SAN JOSE 95118United StatesUSA
- Phone+1 (408) 708-9808
- Fax+1 (302) 655-5049
- Websitehttps://www.anixa.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDxHealth SA - ADR | 75.33m | -39.90m | 74.50m | 300.00 | -- | -- | -- | 0.989 | -1.14 | -1.14 | 0.8428 | -0.0357 | 0.5528 | 11.06 | 6.95 | 251,090.00 | -29.28 | -51.62 | -33.98 | -64.72 | 62.76 | 50.88 | -52.97 | -117.64 | 1.53 | -1.54 | 1.02 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
Alpha Teknova Inc | 36.85m | -36.06m | 74.71m | 210.00 | -- | 0.896 | -- | 2.03 | -1.05 | -1.05 | 1.05 | 2.04 | 0.2815 | 2.29 | 7.89 | 175,490.50 | -27.54 | -- | -29.30 | -- | 27.36 | -- | -97.85 | -- | 3.92 | -28.23 | 0.1365 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
Provectus Biopharmaceuticals Inc | 590.75k | -2.78m | 75.08m | 4.00 | -- | -- | -- | 127.09 | -0.0066 | -0.0066 | 0.0014 | -0.0178 | 0.4221 | -- | 1,358.05 | 147,687.50 | -198.50 | -276.33 | -- | -- | -- | -- | -470.31 | -1,667.76 | -- | -10.24 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
Atara Biotherapeutics Inc | 34.70m | -233.11m | 75.14m | 173.00 | -- | -- | -- | 2.17 | -2.12 | -2.12 | 0.3016 | -0.817 | 0.1485 | 0.9947 | 1.92 | 154,240.00 | -99.76 | -70.20 | -213.09 | -86.94 | 69.30 | -- | -671.70 | -1,559.33 | 0.50 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Bakhu Holdings Corp | 0.00 | -1.92m | 75.33m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
Celularity Inc | 14.79m | -181.41m | 75.37m | 225.00 | -- | 2.22 | -- | 5.10 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
Aileron Therapeutics Inc | 0.00 | -18.07m | 75.78m | 15.00 | -- | 1.32 | -- | -- | -3.19 | -3.19 | 0.00 | 5.42 | 0.00 | -- | -- | 0.00 | -31.05 | -65.99 | -33.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Marinus Pharmaceuticals Inc | 28.29m | -145.34m | 75.81m | 165.00 | -- | -- | -- | 2.68 | -2.64 | -2.64 | 0.5142 | -0.2992 | 0.1554 | 0.8536 | 3.72 | 171,442.40 | -79.82 | -49.64 | -96.93 | -57.76 | 91.22 | -- | -513.80 | -518.96 | 2.93 | -13.62 | 1.29 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
Anixa Biosciences Inc | 210.00k | -10.74m | 77.04m | 4.00 | -- | 3.12 | -- | 366.85 | -0.3451 | -0.3451 | 0.0068 | 0.7749 | 0.0078 | -- | 0.7807 | 52,500.00 | -40.49 | -59.69 | -41.26 | -62.61 | -- | -- | -5,174.29 | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
Cue Biopharma Inc | 7.02m | -49.97m | 79.05m | 53.00 | -- | 2.63 | -- | 11.26 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
Aclaris Therapeutics Inc | 31.12m | -77.26m | 79.10m | 91.00 | -- | 0.5569 | -- | 2.54 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
Elutia Inc | 25.05m | -49.46m | 79.14m | 54.00 | -- | -- | -- | 3.16 | -2.35 | -2.34 | 1.24 | -2.07 | 0.5219 | 2.06 | 4.27 | 463,833.30 | -103.05 | -42.93 | -599.50 | -79.34 | 42.01 | 43.32 | -197.48 | -64.16 | 0.5499 | -1.36 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
Spero Therapeutics Inc | 110.98m | 23.40m | 79.36m | 46.00 | 3.49 | 0.8227 | 3.35 | 0.7151 | 0.4213 | 0.4213 | 2.08 | 1.79 | 0.792 | -- | 3.96 | 2,412,565.00 | 16.70 | -35.52 | 21.73 | -41.75 | -- | -- | 21.09 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
Sellas Life Sciences Group Inc | 0.00 | -35.81m | 80.86m | 16.00 | -- | 8.13 | -- | -- | -1.12 | -1.12 | 0.00 | 0.1721 | 0.00 | -- | -- | 0.00 | -133.77 | -111.48 | -303.59 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
Annovis Bio Inc | 0.00 | -47.53m | 81.44m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
Maia Biotechnology Inc | 0.00 | -23.72m | 81.67m | 13.00 | -- | -- | -- | -- | -1.57 | -1.57 | 0.00 | -0.2801 | 0.00 | -- | -- | 0.00 | -266.70 | -- | -520.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -21.91 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.38m | 4.33% |
Laird Norton Wealth Management LLCas of 31 Mar 2024 | 604.24k | 1.89% |
UBS Financial Services, Inc.as of 31 Mar 2024 | 536.24k | 1.68% |
Mission Wealth Management LPas of 31 Mar 2024 | 502.42k | 1.58% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 340.95k | 1.07% |
Geode Capital Management LLCas of 31 Mar 2024 | 320.15k | 1.00% |
Long Focus Capital Management LLCas of 31 Mar 2024 | 165.70k | 0.52% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 149.60k | 0.47% |
Jane Street Capital LLCas of 31 Mar 2024 | 121.92k | 0.38% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 116.91k | 0.37% |